American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

March 24, 2022

NYSE American US Health Care Health Care Providers and Services earnings 18 min

Earnings Call Speaker Segments

Stephanie Prince

executive
#1

Thanks, Chad, and I appreciate all of you being with us today. Ahead of handing things to management, I'd like to offer a few comments about forward-looking statements. Be aware that any remarks given during this conference call regarding the company's expectations, plans, and prospects for the future count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual outcomes could differ materially from what those forward-looking statements suggest, owing to a number of significant factors, among them the ones covered in the company's SEC filings; that includes the annual report on Form 10-K covering the year that ended December 31, 2020, the quarterly reports on Form 10-Q covering the quarters that ended March 31, June 30, and September 30, each in 2021, plus a definitive proxy statement for the Annual Meeting of Shareholders held on June 25, 2021. No obligation is assumed by the company to update any information in this conference call. At this point I'd like to hand the call to Ray Stachowiak, CEO of AMS. Ray?

Ray Stachowiak

executive
#2

Thanks, Stephanie, and good afternoon to all of you. We appreciate your participation today in this conference call covering our 2021 fourth quarter and year-end earnings. I'll make a few opening comments, after which I'll pass things to Alexis Wallace, our Chief Accounting Officer, who will walk through the financial review. Then Craig Tagawa, our President, CEO and CFO, will give an operational review of the results. Once those prepared remarks are done, Craig, Alexis, Ernie Bates — our Senior Vice President, Sales and Business Development and International operations — and I will take your questions. AMS ended 2021 strongly, posting the year's largest revenue figure during the fourth quarter. For the quarter, revenue came in at $4.7 million, and for the year, it totaled $17.6 million. Operating income reached $723,000, marking a fourth straight profitable quarter versus losses a year earlier, and it was $1.4 million across the full year. Craig and Alexis will cover the specifics shortly. We got a lot done during 2021. Among the steps we took: we bolstered the balance sheet via the impaired asset write-down in December 2020, and we refinanced our debt. That refinancing with Fifth Third Bank last April brought down our principal payments and interest expense considerably. We also set up a $7 million line of credit, which adds to the resources available for new business opportunities. Our product lines grew broader, allowing us to supply radiation therapy equipment from every manufacturer. On top of that, we widened our addressable market by entering a business development agreement that gives us support as we chase new advanced radiation therapy opportunities within the federal facilities market, including VA and Department of Defense hospitals. That comes alongside our other marketing initiatives across United States and international health care markets. Near the end of last year, we trimmed expenses even more by subleasing our downtown San Francisco office, adding to our other cost control efforts. Taken together, these moves produced greater profitability and brought net income back into positive territory for both the quarter and the year. We hold substantial resources for upcoming opportunities: $8.3 million in cash plus the new $7 million line of credit; these assets can be leveraged even further to speed up growth in our business. I'll hand the call to Alexis now for the fourth quarter and full year financial review. Alexis?

Alexis Wallace

executive
#3

Thank you, Ray, and good afternoon to all of you. Prior to starting my prepared remarks, I want to direct your attention to the earnings press release for our fourth quarter and year-end 2021, which came out earlier this morning. Should you require a copy, you can find it on our website, ashs.com, under the Investors tab at Press Releases. Now moving on to our fourth quarter results: during the 3 months that ended December 31, 2021, revenue rose 1.8% to $4.689 million, up from $4.608 million in the fourth quarter of 2020. Turning to our proton therapy installation at Orlando Health in Florida: Q4 revenue there rose 20.1%, reaching $1.685 million, up from $1.403 million during the same quarter in 2020. As for total proton therapy fractions, we recorded 1,113 in the fourth quarter — a 7.9% decrease from the 1,209 fractions logged in Q4 of 2020. Meanwhile, revenue tied to our Gamma Knife business came in at $3.004 million for the fourth quarter of 2021, a 6.3% drop from $3.205 million a year earlier. Gamma Knife procedures totaled 369 in that quarter, falling 13.6% from 427 during the comparable period the year before. Gross margin in the fourth quarter of 2021 rose 116% to $2.218 million, or 47.3% of revenue, compared with gross margin of $1.027 million, or 22.3% of revenue, in the fourth quarter of 2020. Selling and administrative costs grew by 17.7% to $1.238 million for the 3-month period, versus $1.052 million during the same period in the prior year. Interest expense declined 40.2% to $152,000, compared with $254,000 for the same period in the prior year. Operating income in the fourth quarter of 2021 came to $723,000, versus an operating loss of $8.543 million in the fourth quarter of 2020. Included in those results are write-downs for impaired assets: $105,000 during Q4 2021 and $8.264 million during Q4 2020. If you set aside those write-downs, non-GAAP operating income came to $828,000, versus a loss of $279,000 — that's an improvement of $1.107 million. For Q4 2021, net income reached $219,000, equal to $0.04 per diluted share, while Q4 2020 showed a net loss of $6.231 million, or $1.01 per diluted share. Weighted average common shares outstanding on a fully diluted basis totaled 6,117,000 in Q4 2021 and 6,154,000 in Q4 2020. Adjusted EBITDA for Q4 2021 was $2.150 million, down from $2.538 million in Q4 2020. Closing out 2021 on December 31, we held $8,263 million across cash, cash equivalents, and restricted cash. That's up against the $4.325 million we reported on the same date in 2020. Equity attributable to shareholders stood at $24,239 million as of December 31, 2021, working out to $4.01 for each share still outstanding. For comparison, at the close of 2020 that figure was $23.650 million, which translated to $4.08 per share outstanding. Taking the full 12-month period in short, revenue slipped 1.2%, landing at $17.628 million. Proton therapy revenue moved down 1.8%, finishing at $6.58 million. Total proton therapy fractions reached 4,426, a 24.6% drop across the year. The bulk of that decrease stemmed from COVID-19's continuing impact, plus time lost to repairing equipment components during the year's second half. Gamma Knife revenue fell 0.4%, landing at $11.629 million. Gamma Knife procedures totaled 1,436, which represents a 6.1% decline. When looking at same-center figures, Gamma Knife volumes rose 6.9% versus the prior year. For 2021, operating income reached $1.351 million, versus an operating loss of $9.463 million in 2020, and that 2020 figure includes the write-down of impaired assets I referred to earlier. Non-GAAP operating income, once the write-down is excluded, came in at $1.456 million, compared with a loss of $1.199 million, which is a favorable swing of $2.655 million. At this point I'll hand the call to Craig for the operational overview of the fourth quarter. Craig?

Craig Tagawa

executive
#4

Thanks, Alexis, and good afternoon to all of you. As Alexis said, our total revenue for the fourth quarter came in at $4.7 million, which is a 1.8% rise compared with last year; that made it the strongest revenue quarter of the year, and it largely mirrors somewhat softer volumes that were offset by better reimbursements. In Florida, fourth quarter revenue from our proton therapy system grew 20.1% to $1.7 million. A higher average reimbursement per fraction was offset by somewhat fewer fractions, which fell 7.9% year-over-year to 1,113 during the quarter. Volume remained affected by continuing downtime needed to repair components of the proton system, and that work was finished in October 2021. Gamma Knife revenue fell 6.3% to $3 million. That decline stemmed from fewer procedures, offset by a higher average reimbursement. The higher average reimbursement resulted from the expiration of an agreement in the fourth quarter of 2020 that had been reimbursed at a lower rate, along with a higher average rate at the company's retail sites. Gamma Knife procedures dropped by 13.6% to 369 in the fourth quarter, mainly because of the expiration of 2 agreements, 1 in the fourth quarter of 2020 and the other in the first quarter of 2021, both of which were high-volume customers. On a same-center basis, gamma volumes at the same centers that were operating were even with Gamma Knife volumes at those same centers in the comparable period a year earlier, which leaves out the 2 agreements that expired. Gross margin rose 116% in dollars to $2.218 million. The gross margin percentage also more than doubled, reaching 47.3% of revenue versus 22.3% in the fourth quarter of 2020. That gain was mainly driven by a 29.4% drop in depreciation and amortization and a 46.3% drop in other direct operating costs, which reflects the ongoing benefits of the 2020 year-end balance sheet restructuring, the 2 agreement expirations and lower operating costs at the company's existing retail sites. Selling and administrative costs rose by 17.7% to $1.2 million for the quarter; that came from higher legal and related fees tied to the pursuit of new business opportunities. Interest expense declined 40.2% year-over-year to $152,000, reflecting the debt refinancing we finished last April, which significantly reduced the interest rate on the portfolio. Non-GAAP operating income for the fourth quarter was $828,000, compared with a loss of $279,000 last year; that is a positive swing of $1.1 million, reflecting lower total direct operating costs and interest expense. These figures exclude the impaired asset write-downs we've been discussing of $105,000 and 800 — $8.264 million in the fourth quarter of 2021 and 2020, respectively. During the first and fourth quarter of 2021, we completed Cobalt-60 reloads for 2 existing customers that extended their agreements for 5 years. The Icon upgrade at Gamma Knife Center Ecuador is slated for installation later this year, subject to regulatory approvals; it will be one of the few Gamma Knife Icon units anywhere in South America. Growing our lineup of radiation therapy products and the markets we serve has contributed to a bigger pipeline of new business, and talks are ongoing with clients we already have as well as prospects about these more advanced offerings. As Ray noted, operating income came in positive for a fourth quarter in a row. The financial steps taken during this year have placed us on solid ground and in a strong position to keep that important trend going. That wraps up the formal portion of what we have to present. Chad, at this point we would like to hand the call back to you and begin taking questions.

Ray Stachowiak

executive
#5

Appreciate that, Chad, and I want to thank all of you for being here with us right now. AMS closed out the year carrying solid momentum, and in our view, we sit in a strong spot to capture growth ahead. We're eager to talk with all of you once more during our conference call for the first quarter, which happens in mid-May. Should anything come up before then, reach out to us straight away. Take care of yourselves, remain safe. That's all from us.

Operator

operator
#6

Thank you as well, sir. That brings this call to a close. We appreciate your participation in today's presentation. You are free to disconnect at this time.

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.